Arcutis Biotherapeutics, Inc. (ARQT) Revenue History
Annual and quarterly revenue from 2017 to present
ARQT Revenue Over Time (2017–2025)
ARQT Revenue Growth History
3 of 3 years with positive growth- FY2017 revenue growth
- N/A
- FY2018 revenue growth
- N/A
- FY2019 revenue growth
- N/A
- FY2020 revenue growth
- N/A
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- N/A
- FY2023 revenue growth
- +1517.1%
- FY2024 revenue growth
- +229.7%
- FY2025 revenue growth
- +91.3%
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $105.4M | +60.1% |
| Q4 2025 | $129.5M | +81.5% |
| Q3 2025 | $99.2M | +121.7% |
| Q2 2025 | $81.5M | +164.1% |
| Q1 2025 | $65.8M | +32.8% |
| Q4 2024 | $71.4M | +427.6% |
| Q3 2024 | $44.8M | +17.4% |
| Q2 2024 | $30.9M | +494.6% |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2023)
ARQT's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
ARQT Revenue Analysis (2017–2025)
Current Revenue & Growth
As of June 21, 2026, Arcutis Biotherapeutics, Inc. (ARQT) generated trailing twelve-month (TTM) revenue of $415.6 million, reflecting explosive growth of +60.1% year-over-year. The most recent quarter (Q1 2026) recorded $105.4 million in revenue, down 18.6% sequentially.
Historical Growth Trajectory
ARQT's historical revenue data shows a 3-year CAGR of +367.3%. Arcutis Biotherapeutics, Inc.'s highest annual revenue of $376.1 million was recorded in 2025, an all-time high.
Revenue by Segment
ARQT's revenue is primarily driven by Other Revenue (51%), and Product (49%). With over half of revenue concentrated in Other Revenue, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including DERM (+15.0% YoY), NVCR (+8.5% YoY), and PRGO (-3.6% YoY) — ARQT has outperformed the peer group in revenue growth. Compare ARQT vs DERM →
ARQT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARQTCurrent | $416M | +60.1% | - | -3.3% | |
 DERM | $62M | +15.0% | +6.8% | -13.2% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 PRGO | $4.3B | -3.6% | +0.8% | 8.1% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 DAWN | $158M | +20.6% | - | -80.8% |
ARQT Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $376.1M | +91.3% | $339.4M | 90.2% | $-12,227,000 | -3.3% |
| 2024 | $196.5M | +229.7% | $177.4M | 90.3% | $-128,397,000 | -65.3% |
| 2023 | $59.6M | +1517.1% | $54.6M | 91.6% | $-241,101,000 | -404.5% |
| 2022 | $3.7M | - | $2.9M | 79.5% | $-301,627,000 | -8183.0% |
| 2021 | $0 | - | $-763,000 | - | $-206,529,000 | - |
| 2020 | $0 | - | $-455,000 | - | $-136,645,000 | - |
| 2019 | $0 | - | $-195,000 | - | $-43,132,000 | - |
| 2018 | $0 | - | $0 | - | $-19,735,000 | - |
| 2017 | $0 | - | $0 | - | $-4,106,000 | - |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
9+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ARQT — Frequently Asked Questions
Quick answers to the most common questions about buying ARQT stock.
Is ARQT's revenue growth accelerating or slowing?
ARQT revenue growth is accelerating. TTM revenue reached $416M, up +60.1% year-over-year — ahead of the 5-year CAGR of N/A. This indicates the business is expanding faster than its historical baseline.
What is ARQT's revenue history from 2017 to 2026?
Arcutis Biotherapeutics, Inc. (ARQT) revenue history spans 2017 to 2026. TTM revenue as of 2026 is $416M, growing at +60.1% YoY. The 5-year CAGR is N/A. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ARQT's long-term revenue growth rate (CAGR)?
Arcutis Biotherapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained nature of its business expansion. As of 2026, the current YoY growth rate of +60.1% is above this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ARQT.
Why does ARQT's quarterly revenue fluctuate?
ARQT quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Arcutis Biotherapeutics, Inc.'s revenue data from 2017 to 2026 shows full historical quarterly detail on this page.
How is ARQT's revenue distributed by segment?
ARQT reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ARQT's revenue compare to industry peers?
Arcutis Biotherapeutics, Inc. (ARQT) with TTM revenue of $416M and +60.1% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.